CombiGene: Valuation report to be published Dec 14th
A valuation report of CombiGene AB will be published Dec 14th 2015 by the New York based financial services firm Arrowhead Business and Investment Decisions, LLC (ABID).
The independent analysis and valuation has been commissioned by CombiGene and is based on the collection and analysis of public information and public company disclosures. The release will be made at www.abid.co/AKTO.COMBI on Monday December 14th between 9:00AM and 5:00PM NY time (between 3:00PM and 11:00PM Swedish time). Following that release, the report will be distributed through Arrowhead’s global distribution network which covers more than 50,000 US and international investors. After the release, a link to the report will also be provided on CombiGene’s website www.combigene.com.
For further information:
CombiGene AB (publ)
Bengt Westrin, CEO
Tel: +46 70 265 48 62
email: bengt.westrin@combigene.com
About Arrowhead Business and Investment Decisions
Arrowhead Business and Investment Decisions, LLC is a New York City based provider of equity research and investor relations services. Arrowhead covers several industries and sectors, from healthcare to technology, materials and energy. Arrowhead also operates the financial information platform www.abid.co. Arrowhead’s investor network is composed of recognized pension funds, mutual funds, hedge funds, private equity funds, investment banks, brokerages, venture capital funds and family offices. Further information can be found at www.arrowheadbid.com.
About CombiGene AB
By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. Our current focus is on continuing to develop this method into an effective and safe therapy for epilepsy patients, but the method may also have development potential as a means of treating other neurological disorders. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace AktieTorget. www.combigene.com .
MORE FROM THE COMPANY is a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Other issues of MORE FROM THE COMPANY and PRESS RELEASES are available at www.combigene.com.